PR Newswire (Wed, 7:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (May 6, 2013)
-
PR Newswire (May 3, 2013)
-
PR Newswire (Apr 5, 2013)
-
PR Newswire (Mar 21, 2013)
-
-
PR Newswire (Mar 1, 2013)
-
-
PR Newswire (Jan 23, 2013)
-
-
PR Newswire (Jan 4, 2013)
-
PR Newswire (Dec 4, 2012)
-
EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast CancerPR Newswire (Nov 26, 2012)
-
PR Newswire (Nov 14, 2012)
-
PR Newswire (Aug 14, 2012)
-
PR Newswire (Jul 25, 2012)
-
PR Newswire (May 15, 2012)
-
PR Newswire (May 10, 2012)
To learn more about Seeking Alpha Pro, click here.
There are no Transcripts on ENMD.
-
PR Newswire (Wed, 7:00AM)
-
PR Newswire (May 6, 2013)
-
PR Newswire (May 3, 2013)
-
PR Newswire (Apr 5, 2013)
-
PR Newswire (Mar 21, 2013)
-
PR Newswire (Mar 1, 2013)
-
PR Newswire (Jan 23, 2013)
-
PR Newswire (Jan 4, 2013)
-
PR Newswire (Dec 4, 2012)
-
EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast CancerPR Newswire (Nov 26, 2012)
-
PR Newswire (Nov 14, 2012)
-
PR Newswire (Aug 14, 2012)
-
PR Newswire (Jul 25, 2012)
-
PR Newswire (May 15, 2012)
-
PR Newswire (May 10, 2012)
-
PR Newswire (Apr 3, 2012)
-
at MarketWatch.com (Jan 26, 2012)
-
PR Newswire (Jan 23, 2012)
ENMD vs. ETF Alternatives
Company Description
EntreMed, Inc. (“EntreMed” or “the Company”) (Nasdaq: ENMD) is a clinical-stage pharmaceutical company focused on developing ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers, multiple myeloma and... More
